The antibacterial activity of UK-18,892, a new semisynthetic aminoglycoside, was examined against aminoglycoside-susceptible and aminoglycoside-resistant clinical isolates of gram-negative bacilli and Staphylococcus aureus. UK-18,892 had a similar degree of activity to those of amikacin and kanamycin A against aminoglycoside-susceptible bacteria but was less potent than gentamicin against all isolates except Providencia spp. UK-18,892 was highly active against aminoglycoside-resistant bacteria, inhibiting 93% of the 268 isolates examined at 12. 5 ,ug/ml. Amikacin was similarly active, whereas gentamicin inhibited only 14% of these isolates at 12. 5 ,ug/ml.
The aminoglycosides are among the most useful drugs currently available for the treatment of infections due to gram-negative bacilli. Their utility is being threatened, however, by the appearance of resistant bacteria, the majority of which possess enzymes capable of inactivating aminoglycosides by acetylation of amino groups and by adenylylation or phosphorylation of hydroxyl groups. UK-18,892 ( Fig. 1) is a new semisynthetic aminoglycoside derived from kanamycin A, which is active against Staphylococcus aureus and a wide range ofgram-negative bacilli, including strains known to possess aminoglycoside-inactivating enzymes (7) . The purpose of this paper is to report in greater detail the in vitro antibacterial activity of UK-18,892 against clinical isolates of a variety of aminoglycosidesusceptible and aminoglycoside-resistant bacteria and to compare its activity with those of kanamycin A, gentamicin, and amikacin. MBCs. Organisms were grown as described for MIC deterninations. Cultures were diluted in brain heart infusion broth, and approximately 2 x 104 colonyforming units was inoculated into 0.5-ml portions of serial doubling dilutions of the antibiotic in brain heart infusion broth. The tubes were incubated at 37°C for 18 h, and the MIC was recorded. Samples (10 pl) were taken from each tube in which no growth was visible and spread onto Diagnostic Sensitivity Test Agar plates. These were then incubated for 18 h at 370C. The MBC was the lowest concentration of antibiotic which totally prevented growth on subculture.
MATERIALS
Aminoglycosides. 
RESULTS
Activity against aminoglycoside-susceptible bacteria. The in vitro activity of UK-18,892 against 187 isolates of gram-negative bacilli and 31 isolates of S. aureus is shown in Fig.  2 . The MICs of UK-18,892 were 6.25 ,ug/ml or less against all isolates of S. aureus, Escherichia coli, Klebsiella spp., Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Providencia spp., Serratia spp., and P. aeruginosa.
Amikacin exhibited a similar degree of activity, also inhibiting all of these isolates at 6.25 ,tg/ml. published by other workers for gentamicin and amikacin (5) . 892 (Fig. 1) is a synthetic derivative of kanamycin A which exhibits potent activity in vitro against S. aureus and a broad spectrum of gram-negative bacilli. Against aminoglycosidesusceptible bacteria in general, UK-18,892 was either equiactive with (Proteus spp., Klebsiella spp., and S. aureus) or up to 1.5 times more potent than (Providencia spp., Enterobacter spp., and E. coli)Athe parent aminoglycoside, kanamycin A. Against P. aeruginosa, however, UK-18,892 was considerably more potent than kanamycin A.
The low activity of kanamycin A against P. aeruginosa is expected and may be attributable to the widespread occurrence of 3'-phosphorylating activity in this genus (3, 10 (8) . UK-18,892 was also active in vitro against the majority of the aminoglycoside-resistant bacteria examined. At a clinically acceptable concentration (12.5 ,ug/ml), 93% of the 268 isolates were susceptible to UK-18,892. Amikacin showed similar activity (94% sensitive), whereas kanamycin A was practically inactive and gentamicin probably had a clinically useful level of activity against only about 10% of these isolates (Table   1) .
In view of its potent activity in vitro and in vivo (7; unpublished results) against both aminoglycoside-susceptible and aminoglycoside-resistant bacteria, it is concluded that UK-18,892 is a potentially valuable injectable agent for the treatment of serious bacterial infections.
